WallStreetZenWallStreetZen

NASDAQ: IMVT
Immunovant Inc Earnings & Revenue

IMVT earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$243.4M
Current Profit Margin
0%

IMVT Return on Equity

Current Company
-61.1%
Current Industry
-63.5%
Current Market
188%
IMVT's Return on Equity (-61.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when IMVT announces earnings.

IMVT Return on Assets

Current Company
-55.3%
Current Industry
2.9%
IMVT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

IMVT Return on Capital Employed

Current Company
-35.93%
Current Industry
19.5%
IMVT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

IMVT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
IMVT$0.00-$242.72M-$243.45MN/AN/A
NUVL$0.00-$145.13M-$145.51MN/AN/A
IBRX$302.00k-$439.89M-$600.96M+45.07%N/A
KRYS$95.95M$65.04M$57.16MN/AN/A
CRNX$1.97M-$232.29M-$235.46M-3.45%N/A

Immunovant Earnings & Revenue FAQ

What were IMVT's earnings last quarter?

On Invalid Date, Immunovant (NASDAQ: IMVT) reported Q4 2023 earnings per share (EPS) of -$0.36, up 26.53% year over year. Total Immunovant earnings for the quarter were -$51.42 million. In the same quarter last year, Immunovant's earnings per share (EPS) was -$0.49.

If you're new to stock investing, here's how to buy Immunovant stock.

What was IMVT's earnings growth in the past year?

As of Q2 2024, Immunovant's earnings has grown year over year. Immunovant's earnings in the past year totalled -$243.45 million.

What was IMVT's revenue last quarter?

On Invalid Date, Immunovant (NASDAQ: IMVT) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Immunovant's revenue was $0.00.

What was IMVT's revenue growth in the past year?

As of Q2 2024, Immunovant's revenue has grown null year over year. Immunovant's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.